1. Home
  2. INTZ vs NXTC Comparison

INTZ vs NXTC Comparison

Compare INTZ & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intrusion Inc.

INTZ

Intrusion Inc.

N/A

Current Price

$0.69

Market Cap

19.5M

ML Signal

N/A

Logo NextCure Inc.

NXTC

NextCure Inc.

N/A

Current Price

$5.09

Market Cap

17.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
INTZ
NXTC
Founded
1983
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5M
17.3M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
INTZ
NXTC
Price
$0.69
$5.09
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$5.75
★ $23.00
AVG Volume (30 Days)
★ 128.8K
108.0K
Earning Date
05-12-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 71.78
N/A
EPS
★ N/A
N/A
Revenue
$7,015,000.00
★ $22,378,000.00
Revenue This Year
$25.34
N/A
Revenue Next Year
$14.70
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 21.56
N/A
52 Week Low
$0.59
$1.55
52 Week High
$2.27
$15.74

Technical Indicators

Market Signals
Indicator
INTZ
NXTC
Relative Strength Index (RSI) 42.95 41.20
Support Level $0.67 $3.98
Resistance Level $0.89 $8.68
Average True Range (ATR) 0.07 0.78
MACD -0.01 -0.23
Stochastic Oscillator 21.54 14.25

Price Performance

Historical Comparison
INTZ
NXTC

About INTZ Intrusion Inc.

Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: